AZTA - NASDAQ
Azenta, Inc.
$23.89
+2.0%Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
At a Glance
Live SnapshotAzenta, Inc. Management Team
Mr. Lawrence Y. Lin
Executive Vice President & Chief Financial Officer
Mr. John P. Marotta
President, Chief Executive Officer & Director
Compensation
$566,440
Ms. Olga Pirogova
Senior Vice President & Chief HR Officer
Dr. Ginger Zhou Ph.D.
Senior Vice President & President of GENEWIZ
Compensation
$523,886
Mr. J. Robert Woodward
Senior Vice President of Global Quality & Engineering
Mr. Jason W. Joseph J.D.
Senior Vice President, General Counsel & Corporate Secretary
Compensation
$608,083
Ms. Violetta Hughes
Vice President & Chief Accounting Officer
Mr. Luc Provost
Vice President & Chief Executive Officer of B Medical Systems
Ms. Yvonne Perron
Vice President of Financial Planning & Analysis and Investor Relations
Mr. Michael Paulo
Vice President, Chief Information & Digital Officer
Azenta, Inc. Insider Positioning
During the last 12 months, insiders have purchased $234K and sold $133K worth of AZTA shares, resulting in $101K of net buying activity.
3 Months
10.0K
163.80K
0
0.00
+164K
+$164K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
316
9.29K
-9K
-$9K
9-12 Months
2.5K
69.90K
4.3K
123.86K
-54K
-$54K
Top Buyers
Cornog William L
Director
$164K
Lin Lawrence Y.
Officer: Evp, Cfo And Treasurer
$70K
Top Sellers
Zhou Ginger
Officer: Svp And Gm, Multiomics
$62K
Pirogova Olga
Officer: Svp And Chro
$62K
Marotta John
Director, Officer: President And Ceo
$9K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $101K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
3 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Sustained buying momentum: Consistent net buying over multiple quarters suggests insiders maintain conviction in the company's prospects. This is particularly meaningful if buying continued through market volatility.
SEC Filings
AZTA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | December 18, 2025 | January 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | December 17, 2024 | January 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | December 15, 2023 | January 30, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | December 21, 2022 | January 31, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | December 15, 2021 | January 24, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | December 15, 2020 | January 26, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | December 17, 2019 | January 24, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | December 14, 2018 | January 30, 2019 | 2019 | |
DEF 14A DEF 14A 2017 N/A | December 13, 2017 | December 13, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | December 16, 2016 | December 16, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.